Table 1.
Association between baseline characteristics and YEATS4 expression
| Clinicopathological criteria | Expression of YEATS4 | χ2 | P-value | ||
|---|---|---|---|---|---|
|
| |||||
| Positive (n = 325) | Negative (n = 156) | Total (n = 481) | |||
| Age at diagnosis (years) | |||||
| ≤ 35 | 59 (74.7%) | 20 (25.3%) | 79 | 2.184 | 0.139 |
| > 35 | 266 (66.2%) | 136 (33.8%) | 402 | ||
| Pathologic tumor size (cm) | |||||
| T1 | 93 (59.2%) | 64 (40.8%) | 157 | 8.107 | 0.017 |
| T2 | 201 (70.8%) | 83 (29.2%) | 284 | ||
| T3 | 31 (77.5%) | 9 (22.5%) | 40 | ||
| Menopausal status | |||||
| Premenopausal | 138 (65.7%) | 72 (34.3%) | 210 | 0.584 | 0.445 |
| Postmenopausal | 187 (69.0%) | 84 (31.0%) | 271 | ||
| Histological grade | |||||
| 1 | 50 (75.8%) | 16 (24.2%) | 66 | 4.426 | 0.219 |
| 2 | 135 (63.4%) | 78 (36.6%) | 213 | ||
| 3 | 114 (70.4%) | 48 (29.6%) | 162 | ||
| Unknown | 26 (65.0%) | 14 (35.0%) | 40 | ||
| ER | |||||
| Positive | 234 (70.9%) | 96 (29.1%) | 330 | 5.356 | 0.021 |
| Negative | 91 (60.3%) | 60 (39.7%) | 151 | ||
| PR | |||||
| Positive | 206 (64.2%) | 105 (35.8%) | 311 | 0.710 | 0.400 |
| Negative | 119 (70.0%) | 51 (30.0%) | 170 | ||
| HER2 | |||||
| Negative | 243 (66.4%) | 123 (33.6%) | 366 | 0.963 | 0.326 |
| Positive | 82 (71.3%) | 33 (28.7%) | 115 | ||
| Lymph node metastasis | |||||
| Negative | 179 (63.0%) | 105 (37.0%) | 284 | 6.520 | 0.011 |
| Positive | 146 (74.1%) | 51 (25.9%) | 197 | ||
| TNM | |||||
| I | 50 (56.2%) | 39 (43.8%) | 89 | 10.566 | 0.005 |
| II | 215 (67.8%) | 102 (32.2%) | 317 | ||
| III | 60 (80.0%) | 15 (20.0%) | 75 | ||
| Ki-67 status | |||||
| ≤ 20% | 102 (61.8%) | 63 (38.2%) | 165 | 3.789 | 0.052 |
| > 20% | 223 (70.6%) | 93 (29.4%) | 316 | ||
| P53 status | |||||
| Positive | 209 (67.9%) | 99 (32.1%) | 308 | 0.944 | 0.624 |
| Negative | 100 (65.8%) | 52 (34.2%) | 152 | ||
| Unknown | 16 (76.2%) | 5 (23.8%) | 21 | ||
| Molecular subtype | |||||
| Luminal A | 67 (73.6%) | 24 (26.4%) | 91 | 7.388 | 0.061 |
| Luminal B | 186 (69.9%) | 80 (30.1%) | 266 | ||
| HER2 type | 46 (59.0%) | 32 (41.0%) | 78 | ||
| TNBC | 26 (56.5%) | 20 (43.5%) | 46 | ||
YEATS4, YEATS domain-containing protein 4; TNM, tumor-node-metastasis; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer. P-values that reach significance are in bold.